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Abstract: The discovery of novel intronic variants in the ABCA4 locus has contributed significantly
to solving the missing heritability in Stargardt disease (STGD1). The increasing number of variants
affecting pre-mRNA splicing makes ABCA4 a suitable candidate for antisense oligonucleotide (AON)-
based splicing modulation therapies. In this study, AON-based splicing modulation was assessed
for 15 recently described intronic variants (three near-exon and 12 deep-intronic variants). In total,
26 AONs were designed and tested in vitro using a midigene-based splice system. Overall, partial or
complete splicing correction was observed for two variants causing exon elongation and all variants
causing pseudoexon inclusion. Together, our results confirm the high potential of AONs for the
development of future RNA therapies to correct splicing defects causing STGD1.
Keywords: antisense oligonucleotide; ABCA4; Stargardt disease; inherited retinal diseases; splicing
modulation; RNA therapy; deep-intronic; near-exon; pseudoexon; exon elongation
1. Introduction
Stargardt disease (STGD1, OMIM: 248200) is characterized by progressive degener-
ation of the retina. Although STGD1 is usually considered a juvenile disease, the age of
onset depends on the severity of the combination of variant(s) [1–6]. STGD1 patients can
experience a diverse range of clinical manifestations from severe visual impairment to
complete blindness. The three main clinical features include progressive degeneration
of the central macula, presence of autofluorescent lipofuscin flecks distributed across the
macula, and surprising preservation of the tissue surrounding the optic nerve [7].
STGD1 is caused by biallelic mutations in the ABCA4 locus. The 50-exon gene en-
codes the ATP-binding cassette subfamily A member 4 (ABCA4) protein, which plays
a crucial role in photoreceptor cell maintenance. ABCA4 is a transmembrane protein
located in the rims of the outer segment discs in rods and lamellae in cones [8]. It func-
tions as a flippase transporter and facilitates the removal of potentially toxic retinoic acid
derivatives generated during the visual cycle from the lumen to the photoreceptor cell
cytosol [9]. Therefore, ABCA4 dysfunction drives the accumulation of the toxic derivatives
and accelerates the formation of toxic bisretinoids compounds such as N-retinylidene-N-
retinyl-phosphatidyl-ethanolamine (A2PE) in the photoreceptor outer segment. A2PE is
hydrolyzed to N-retinylidene-N-retinyl-ethanolamine (A2E) upon phagocytosis of photore-
ceptor outer segments by the retinal pigmented epithelium (RPE) cells. This increases the
oxidative damage triggered by the A2E as part of lipofuscin accumulation in the RPE cell,
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causing cellular damage and consequently, photoreceptor cell death and progressive loss
of vision [10–12].
The phenotypic and allelic heterogeneity of STGD1 complicates a proper genetic
diagnosis. In the past, genetic testing was focused on the coding regions of a gene. In
recent years, next-generation sequencing has allowed the sequencing of exons and in-
trons, which has led to new insights. For instance, in 448 STGD1 cases found to carry
two ABCA4 alleles after next-generation sequencing, 11% and 10% of the causal alleles
consisted of deep-intronic and non-canonical splice site (NCSS) variants, respectively [13].
The combination of in-depth ABCA4 sequencing, in silico evaluation using splice prediction
tools and midigene-based splice assays, has contributed to solving the missing heritabil-
ity present in STGD1. So far, over 1200 STGD1-causing variants in ABCA4 have been
reported (https://databases.lovd.nl/shared/genes/ABCA4, last accessed day 22 April
2021) [14–20]. Pathogenic intronic and NCSS variants can result in aberrant splicing. Such
variants are excellent candidates for antisense oligonucleotide (AON)-based splicing mod-
ulation therapeutic strategies. Our group and others have previously demonstrated the
great potential of AONs to rescue the effect of mutations disrupting the splicing process
in several inherited retinal disease-associated genes, i.e., CEP290 [21–26], USH2A [27],
CHM [28], OPN1 [29] and ABCA4 [18,30–32].
Recently, 15 novel ABCA4 intronic variants have been reported [13,17,31,33]. Three
variants were classified as near-exon variants and 12 as deep-intronic variants. In the case
of the first group, variants c.1937+37C>G, c.3191-11T>A and c.4352+61G>A have been
described to cause an exon elongation in the final transcript [13,17,31]. In contrast, the
12 deep-intronic variants alter the pre-mRNA splicing by inserting a pseudoexon (PE) into
the final mRNA, causing a frameshift and premature termination of translation.
Here, we report the design of a set of AONs able to redirect the splicing defects
caused by these 15 recently described ABCA4 intronic variants, thereby providing new
opportunities for further therapeutic development of STGD1.
2. Results
2.1. Design of Antisense Oligonucleotides
Fifteen variants disrupting ABCA4 splicing were selected for rescue studies using
AONs. All variants were confirmed as STGD1-causing variants and their effect at RNA level
was validated by in vitro splice assays using midigenes [13,17,19,31,33–35] (Supplementary
Table S1). A total of 26 AONs and one scramble-oligonucleotide (SON) modified with
2′-methoxyethyl and phosphorothioate (2′-O-MOE-PS) were tested in the midigenes har-
boring one of the 15 corresponding variants (Table 1). From the 26 AONs, 24 were newly
designed and the last 2 AONs (AON4 and AON17) were from a previous study for
c.4539+2001G>A and c.4539+2028C>T variants [30,32]. They were used in this study to
assess their splicing rescue efficacy for the c.4539+2064C>T and c.4539+2065C>G splicing
defects. For the near-exonic variants, the AONs were designed to block the aberrant splice
site that was created by each variant, preventing accessibility of the spliceosome. For the
deep-intronic variants, the best strategy involved targeting strong exonic splicing enhancer
(ESE) motifs present within the PEs (Figure 1, Supplementary Figure S1) [36].
Two AONs were used for each variant, except for c.3191-11T>A, c.859-640A>G and
c.859-546G>A. The c.3191-11T>A variant is located 11 nt upstream of exon 22. The variant
is in close proximity to cis-acting splice regulatory features such as the splicing acceptor
site (SAS), the branch point, and high-density splice enhancer motifs. The presence of
crucial splice governing features allowed the design of only a single AON for this variant
(Figure 1A). The c.859-640A>G and c.859-546G>A variants caused overlapping PEs; 46 nt
and 141 nt in size, respectively. Three AONs were designed to eliminate these PEs in
intron 7 (Figure 1C).
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Table 1. Antisense oligonucleotide (AON) sequences and characteristics for the 15 intronic ABCA4 variants with the corresponding
RNA defect.
Variant AON# Sequence (5′ to 3′) L Tm GC % Cor-rection RNA Defect
c.1937+37C>G AON1 CCGUGUCAUGGAGGAGGAUC 20 55.9/64.0 60 100.00 36-nt exon elongation
AON2 CCAUUACCGUGUCAUGGAGGA 21 54.4/49.2 52 84.64
c.3191-11T>A AON1 GCACUAGAAGGACGGGAG 18 52.6/58.0 61 0.00 9-nt exon elongation
c.4352+61G>A AON1 GAACUCACCGUUGGGUCCU 19 53.2/60.0 58 28.40 57-nt exon elongation
AON2 UCUUGAACUCACCGUUGG 18 48/54.0 50 67.07
c.67-2023T>G AON1 UGCGGCAACAUCUAUCUGG 19 51.1/58.8 53 11.47 243-nt PE inclusion
AON2 CAUCAGUGGGUAAGGCUG 18 50.3/56.0 56 87.54
c.570+1798A>G AON1 CUGGAAGUCAUCAAGGCAUUG 21 52.4/47.3 48 100.00 65-nt PE inclusion
AON2 GACUUGAGUUUUACGAGCUG 20 49.7/58.0 45 100.00
c.769-788A>T AON1 GGAAUCACUGAUCCUAGAGG 20 51.8/60.0 50 92.72 162-nt PE inclusion
AON2 GGAUGUGGAAGUCCCCAGG 19 55.4/62.0 63 93.11
c.859-640A>G AON1 CCAGUUCUUGGGUUCUGUUG 20 51.8/60.0 50 100.00 46-nt PE inclusion
AON2 CACCAAGAUGGGGAUACUGG 20 53.8/62.0 55 100.00
AON3 CCUCUCUUCUUCUAGUCUCC 20 51.8/60.0 50 24.34
c.859-546G>A AON1 CCAGUUCUUGGGUUCUGUUG 20 51.8/60.0 50 100.00 141-nt PE inclusion
AON2 CACCAAGAUGGGGAUACUGG 20 53.8/62.0 55 100.00
AON3 CCUCUCUUCUUCUAGUCUCC 20 51.8/60.0 50 100.00
c.2588-706C>T AON1 ACUGGACUGUCUAUUCCUCG 20 51.8/60.0 50 93.83 134-nt PE inclusion
AON2 UCUUUAUCUCCACCGCUCUG 20 51.8/60.0 50 100.00
c.2919-826T>A AON1 CAGCUCUCUGACCUUAUCAGU 21 52.4/47.3 48 47.33 133-nt PE inclusion
AON2 GCUCUGUCCCUGAGUUCUG 19 53.8/60.0 58 100.00
c.3050+370C>T AON1 CAGAGUCCCAUAUUCUCAGG 20 51.8/60.0 50 61.28 205-nt PE inclusion
AON2 GGAUCGAUCAGCUGCUCUG 19 53.2/60.0 58 71.07
c.4539+2064C>T AON4 GGGGCACAGAGGACUGAGA 19 55.4/62.0 63 100.00 345-nt PE inclusion
AON17 GCCAAGAGCUCAGGGUACAG 20 60/64.0 55.9 72.35
c.4539+2065C>G AON4 GGGGCACAGAGGACUGAGA 19 55.4/62.0 63 100.00 170-nt PE inclusion
AON17 GCCAAGAGCUCAGGGUACAG 20 60/64.0 55.9 55.77
c.4634+741A>G AON1 UCUGAUACGGGCUGCCAAAG 20 53.8/62.0 55 100.00 127-nt PE inclusion
AON2 UCCUUAGGAUCCUCUCUCCU 20 51.8/60.0 50 100.00
c.6283-78G>T AON1 GGCAAUGACAGAAUUCUCCUC 21 52.4/47.3 48 100.00 203-nt PE inclusion
AON2 GCUGACAGAAGGCGCACAC 19 55.4/62.0 63 100.00
N/A SON CGCCAAUUGCAAGGUGAUUCC 21 54.4/49.2 52 N/A N/A
L: Length in nt; Tm: theoretical melting temperature in ◦C calculated with OligoCalc (left) and provided by the manufacturer (right); GC:
percentage of GC; % Correction: percentage of observed splicing correction for each AON.
2.2. AON-Driven Splicing Modulation for Near-Exon Variants
The three near-exon variants each generated 100% mis-spliced transcript without any
detectable correct transcripts. The c.1937+37C>G variant is located in ABCA4 intron 13 and
creates a new strong cryptic splice donor site (SDS), causing a 36-nt exon elongation. This
exon elongation introduces a premature stop codon (p.Phe647*) [13]. The c.3191-11T>A
variant causes an exon extension including 9 nt upstream of the exon 22 SAS, leading
to the incorporation of four new amino acids (p.(Gly1064delinsValProProGly)) [31]. The
c.4352+61G>A variant strengthened the existing cryptic SDS, causing a 57-nt exon elon-
gation and introduction of premature stop codon (p.Glu1452*) [17]. As mentioned before,
two AONs were designed to modulate the effects of c.1937+37C>G and c.4352+61G>A,
whereas only one AON was designed to reverse the effect of c.3191-11T>A (Table 1,
Figure 1). All tested AONs did not cause mis-splicing events in the wild-type (WT) se-
quence for all three variants (Figure 2). The pathogenic exon elongation due to
c.1937+37C>G was completely abolished with AON1 (100% correction) and almost com-
pletely abolished with AON2 (85% correction) (Figure 2A, Supplementary Figure S2A).
The 9-nt exon elongation due to c.3191-11T>A was resistant to the effect of the AON as
the correct transcript was not detected at all (Figure 2B, Supplementary Figure S2B). The
failure to restore the correct transcript was likely the result of the limitations imposed by
the region of interest sequence, which allowed the design of only a single AON. The last
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near-exon variant tested was c.4352+61G>A. AON1 and AON2 shared 14 nt of overlapping
target sequence (Supplementary Figure S1). The AON2 outperformed AON1, however,
neither were able to completely rescue aberrant splicing (AON1 showed 28% of correction
whereas AON2 showed 67%) (Figure 2C, Supplementary Figure S2C).




Figure 1. Schematic representation of the different splicing alterations caused by 15 intronic ABCA4 variants and the re-
spective position of the designed 26 antisense oligonucleotides (AONs) in this study. (A) Position of the AONs targeting 
exon elongation caused by the indicated near-exon variants. (B) Position of the AONs targeting the corresponding pseudo-
exon (PE) inclusion caused by the indicated deep-intronic variants in unique regions. (C) Position of the AONs targeting 
the corresponding pseudoexon (PE) inclusion caused by the indicated deep-intronic variants in the same region. 
Figure 1. Schematic representation of the different splicing alterations caused by 15 intronic ABCA4 variants and the
respective position of the designed 26 antisense oligonucleotides (AONs) in this study. (A) Position of the AONs targeting
exon elongation ca sed by the indicated near-exo variants. (B) Position of the AONs targeting the corresponding
pseudoexon (PE) i clusion caused by the indicated deep-intronic variants in unique regions. (C) Position of the AONs
targeting the corresponding pseudoexon (PE) inclusion caused by the indicated deep-intronic variants in the same region.
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Figure 2. Antisense oligonucleotide (AON)-mediated rescue for near-exon splice variants causing exon elongation. Anal-
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type (WT) midigenes and the corresponding mutant midigenes containing near-exon variants c.1937+37C>G (A) c.3191-
i re . tis li l ti ( )- ediated rescue for near-exon splice variants causing exon elongation. Analysis
of splicing correction by reverse transcription polymerase chain reaction (RT-PCR) upon AON (A#) delivery. Wild-type
(WT) midigenes and the corresponding mutant midigenes containing near-exon variants c.1937+37C>G (A) c.3191-11T>A
and (B) c.4352+61G>A (C) were transfected in HEK293T. Non-transfected HEK293T were used as endogenous expression
control (END). The different AONs and a SON were then delivered, except for the non-treated lanes (NT). Genomic region
of the different midigenes is depicted on top of each representative RT-PCR image, whereas the graphs next to each panel
represent the semi-quantification of the resulting RT-PCR products, showing the percentage of correct and exon elongation
transcripts. Exon elongation caused by two out of the three near-exon variants was efficiently rescued by at least one AON.
MQ shows the negative control of the PCR reaction and amplification of exon 5 of the rhodopsin (RHO) gene was used as a
transfection control. Data (n = 2) are presented as mean ± SD. Statistical significance is indicated as ** p < 0.01, *** p < 0.001
and **** p < 0.0001 using one-way ANOVA.
2.3. AON-Driven Splicing Modulation for Deep-Intronic Variants
For three variants, c.570+1798A>G, c.4634+741A>G, and c.6283-78G>T, creating a
65-nt, 127-nt, and 203-nt PE insertion, respectively [13] (Figure 1), all tested AONs were
able to fully restore the correct transcript (Figure 3B,G,H; Supplementary Figure S3B,G,H).
For each variant, two unique AONs targeted either the intron/PE boundary or high-scored
SC35 sequence motifs located within the PE (Supplementary Figure S1). The c.2588-706C>T
variant caused the insertion of a 134-nt PE in intron 16 [13] and the two AONs tested
had a high rate of splicing correction (Figure 3D, Supplementary Figure S3D). Overall,
AON1 almost completely eliminated the presence of the PE (94% of correction). For AON2,
which targeted the strongest SC35 site within the PE, 100% of the correct transcript was
achieved. The 162-nt PE introduced by the c.769-788A>T variant was almost completely
excluded from the final transcript (AON1 and AON2 reached 92% and 93% of correction,
respectively) (Figure 3C, Supplementary Figure S3C).
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The c.2919-826T>A variant is described to strengthen a cryptic SDS, causing the in-
clusion of a 133-nt PE into the final transcript [17]. Upon AON2 transfection, aberrant
splicing was completely restored, showing a significant correction efficiency (100% correc-
tion) (Figure 3E, Supplementary Figure S3E). However, the observed splicing correction
for AON1 was less efficient and only increased the correct transcript from 47% up to 72%
(47% of correction) (Figure 3E). Interestingly, the difference in splicing correction seems to
correlate with the targeted region. AON1 targets one SC35 and the newly created SDS by
the c.2919-826T>A variant, whereas the target sequence of AON2 corresponds to a region
containing a high-scored SC35 motif (Supplementary Figure S1).
The c.67-2023T>G variant, located in intron 1 of ABCA4, is expected to cause an
insertion of a 243-nt PE (from here on referred to as PE1) (Figure 1). Surprisingly, an-
other intense lower band was also identified, which has not been described to date
(Figure 3A). The other band represents a 46-nt long PE (from here on referred to as PE2).
The PE2 uses the same cryptic SDS, which was created due to the c.67-2023T>G substitution.
However, the PE2 SAS is located at c.67-2069, while the one of PE1 is at position c.67-2266
(Supplementary Figure S3A). The AON1 targeted the cryptic SAS for PE1 and the AON2
targeted the cryptic SAS for the PE2 (Supplementary Figure S1). AON1 and AON2 were
able to diminish the presence of the PE1 down to 16% and 0% from 57% in the NT control,
respectively. As expected, AON1 failed to correct the insertion of PE2. It was observed
that reduction in PE1 due to AON1 resulted in an increase of PE2 intensity accompanied
by a slight increase in the correct transcript, which was not statistically significant. AON2
completely eliminated the presence of the PE2 and increased the correct transcript from
27% in the NT control to 90% after the treatment.
To correct aberrant splicing caused by the c.3050+370C>T variant, two different AONs
were tested. The target sequences corresponded to two different SC35 motifs located in the
predicted 205-nt PE inclusion, caused by the strengthening of a cryptic SDS (Supplementary
Figure S1). However, a second PE inclusion was detected in the non-treated mutant
condition right below the 205-nt PE inclusion (Figure 3F), which was not previously
reported. This transcript showed a shorter PE of 111-nt, which uses a different SAS but
shared the same SDS with the larger PE (Supplementary Figure S3F). Although the AON
design for this region was based on the 205-nt PE inclusion, both AONs showed a significant
rescue of the aberrant transcripts. More concretely, AON1 targets two SC35 motifs at the
beginning of the 205-nt PE, resulting in a decrease of PE1 down to 10% and an increase of
correct transcript up to 61%. In addition to that, the 111-nt PE transcript was increased up
to 30% compared to mutant NT condition (Figure 3F). On the other hand, AON2 targets
one SC35 motif in the middle of PE1 or at the beginning of PE2 (Supplementary Figure S1),
which results in a 70% increase of the correct transcript and significant PE1 transcript
decrease, not affecting the proportion of the PE2 (Figure 3F).
The c.859-546G>A and c.859-640A>G variants are located in intron 7 causing insertions
of overlapping PEs; 141 nt (c.859-546G>A) and 46 nt (c.859-640A>G) (Figure 1). The two
variants use the same, strong intronic SAS located at c.859-685. However, the c.859-640G>A
substitution created a new cryptic SDS. The c.859-546G>A substitution also created a new
SDS at c.859-545. AON1 and AON2 were designed to correct the presence of both PEs.
AON1 targeted the SAS used by both PEs and its 5′ end partially blocked an SC35 site.
AON2 targeted the shared SC35 motif 17 nt downstream of the PE1 and PE2 SAS. AON3
was an AON designed only for c.859-546G>A as its complementary region is found outside
of the PE due to c.859-640A>G (Supplementary Figure S1). The 141-nt PE was success-
fully skipped after treatment with all three AONs. For the 46-nt PE, AON1 and AON2
caused complete rescue of the aberrant transcript. AON3, whose complementary region is
located outside of the 46-nt PE, had lower efficacy as it was expected (24% of correction)
(Figure 4A, Supplementary Figure S4A).
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deep-intronic variants c.859-640A>G/c.859-546G>A (A) and c.4539+2064C>T/c.4539+2065C>G (B) were transfected in
HEK293T. Non-transfected HEK293T were used as endogenous expression control (END). The different AONs and a SON
were then delivered, except for the non-treated lanes (NT). Genomic region of the different midigenes is depicted on top of
each representative RT-PCR image, whereas the graphs below represent the semi-quantification of the resulting RT-PCR
products, showing the percentage of correct and PE-including transcripts. AON1 and 2 could rescue 100% of the correct
transcript for both c.859-546G>A and c.859-640A>G variants, while AON4 completely redirected splicing in the case of
c.4539+2064C>T and c.4539+2065C>G. MQ shows the negative control of the PCR reaction and amplification of exon 5 of
rho opsin (RHO) gene was used as a transfection control. Data (n = 2) are presented as mean ± SD. Statistical significance
is indicated as * p < 0.05, ** p < 0.01, *** p < 0.001 and **** p < 0.0001 using one-way ANOVA.
Variants c.4539+2064C>T and c.4539+2065C>G are located in intron 30 next to
each other, and share a proximal intronic region with the previously described
c.4539+2001G>A (V4) and c.4539+2028C>T (V5) variants. We hypothesized that the most
efficient AONs targeting the latter variants might also be capable of rescuing the 345-nt
PE and the 170-nt PE caused by the variants c.4539+2064C>T (creating a new ESE) and
c.4539+2065C>G (weakening an ESE and creating a new SDS). Therefore, AON4 and
AON17 were chosen as the sequences with the highest correction potential [30,32]. As
depicted in Figure 4B, AON17 showed a decrease of the 345-nt PE from 25% to 10%, and
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from 60% to 30% in the case of the 177-nt PE. On the contrary, AON4 was able to completely
abolish the aberrant transcript generated by both deep-intronic variants. It is important to
note that AON4 and AON17 target two different regions within the PE. Notably, AON17
overlaps with the region where the two variants c.4539+2064C>T and c.4539+2065C>G
are located. This results in a one-nucleotide mismatch between the target region and the
AON, which might explain the partial splicing correction that was observed (Figure 4A,
Supplementary Figure S4A).
3. Discussion
During the last years, whole locus sequencing in STGD1 has revealed a remarkable
amount of intronic variants in ABCA4. Recently, 15 new causative intronic variants have
been reported. Using AON technology, we were able to correct the splicing defect intro-
duced by 14 of these mutations.
More than a thousand disease-causing variants in ABCA4 have been identified in
STGD1 patients [7]. The size of the gene cDNA (approximately 6.88 kb) and this high
allelic heterogeneity increase the difficulty to find a common treatment for the patient
population and pose a challenge for therapeutic development. However, research on
IRDs has opened many opportunities for the development of molecular therapies over
the last several years. In fact, frequently reported intronic variants among STGD1 cases,
which interfere with ABCA4 splicing, have emerged as an attractive target for AON-based
splicing-modulation therapy [37]. In this study, we designed and screened 26 different
AONs targeting 15 recently described intronic variants that are fairly well distributed
amongst different ABCA4 intronic regions. The final aim was to rescue the aberrant splicing
and select the most promising therapeutics to revert the STGD1 phenotype.
As reported in previous studies, AONs with the phosphorothioate (PS) backbone and
2′-OMe (2’-O-methyl) sugar modifications (2′-OMe-PS) can significantly correct aberrant
transcripts in different IRD-associated genes [18,21,22,25–28,30–32]. To date, these mod-
ifications have given great resistance to nucleases and increase binding, and enhanced
AON properties as drug-like molecules. Despite that, the 2′-O-MOE sugar modification
has also been described as appropriate for therapeutic approaches, especially due to the
increased resistance to nucleases and the reduced nonspecific protein binding which can
reduce toxicities [38]. Moreover, a high splicing-switching capacity of the 2′-O-MOE-PS
chemistry when delivered systemically has also been reported [39]. Until very recently,
this modification was not commercially available, and it has rapidly been extendedly used
for many antisense drugs that are now under clinical evaluation [40]. Therefore, due
to recent evidence in antisense drug development, our AON design has been based on
the implementation of 2′-O-MOE-PS chemistry for the in vitro screening. Last, variants
c.4539+2064C>T and c.4539+2065C>G were targeted with the same antisense sequence but
in 2′-O-MOE-PS instead of the previously used 2′-OMe-PS chemistry [30,32].
As shown in Figure 1, the design of AONs targeting near-exon variants is different
and more challenging compared to the AONs targeting deep-intronic variants. For the
near-exon variants, there is an important variant-dependency as the main objective is to
block the newly created splice site, while not interfering with the binding of splice ancillary
proteins to splicing enhancer motifs that facilitate original splicing. This step is crucial as
blocking of regulatory regions may cause a failure in recognizing the exon, consequently
leading to exon skipping and disrupting protein synthesis. In addition, the near-exon
variants are more difficult to target as they are located in close proximity to the canonical
splice sites of the natural exon. AONs in this region might block the canonical splice site
and consequently inhibit the binding of the spliceosome and cause exon-skipping, which
is not the type of splicing modulation aimed for ABCA4. In contrast, this exon/skipping
strategy is used to rescue other alterations at pre-mRNA level. For instance, this approach
has been of high utility in Duchenne muscular dystrophy, where AONs can efficiently
restore the reading frame of the dystrophin gene by blocking splice sites and bypassing the
target exons [41].
Int. J. Mol. Sci. 2021, 22, 4621 10 of 17
As an example, variant c.3191-11T>A was targeted using only one AON due to the
above-mentioned limitations, and consequently, we could not rescue the exon elongation
defect. The variant is in close proximity to cis-acting splice regulatory elements such as the
SAS and the branchpoint and it is surrounded by a high density of splice enhancer motifs.
The risk of blocking the aforementioned features with AONs could result in additional
mis-splicing events such as exon skipping, and, therefore, only one AON was designed
for this variant. However, future attempts to develop new AONs binding near the new
SAS—instead of binding on top of the variant—might still help to avoid its recognition
and to use the canonical SAS of exon 22. On the other hand, AONs targeting variants
c.1937+37C>G and c.4352+61G>A could efficiently rescue exon elongation, showing how
the distance relative to the canonical splice site significantly affects the correction efficiency.
Nevertheless, the difference between blocking the new acceptor site and donor site should
be noted due to recognition by the different spliceosome complexes at the 5′ or 3′ intronic
regions [42], as the involved mechanism might have an impact on splicing modulation
approaches. Recently, it has been shown that stereochemistry of the PS linkage can increase
the potency of AONs [43,44]. In general, stereopure AONs can be more efficacious at
a lower concentration. This could improve the efficacy in all AONs that successfully
redirected splicing. Unfortunately, this concept might not be true for the c.3191-11T>A
variant as the absent efficiency of the AON might be limited by the target region rather
than the purity of the molecule.
Moving on to the deep-intronic variants, AON design was mainly focused on blocking
the enhancer motifs within the PE region. Our results again confirm the high efficiency
of this strategy to rescue aberrant PE-carrying transcripts, instead of blocking the newly
created splice site. A clear example of this is variant c.2919-826T>A. Here, AON1 blocks the
new SDS, whereas AON2 covers two high-scored SC35 motifs within the PE. Interestingly,
only the second AON managed to fully restore correct transcript formation, whereas the
AON1, which is a variant-specific AON, did not reach such correction.
While PE inclusion was completely reverted in most of the cases by at least one of the
designed AONs, 100% splicing correction could not be achieved for variant c.3050+370C>T.
As already commented, the targeting of the 205-nt PE gave rise to the inclusion of a
shorter PE, which was increased by the treatment with AON1 due to its binding to SC35
motifs only present in the larger PE. Considering that splicing is a dynamic and complex
process [42,45–47], it is very difficult to predict alternative events that might be activated
due to the use of splicing modulation molecules. In addition, splicing has been described as
a non-sequential process by in silico real-time visualization approaches [48–50]. Therefore,
the detection of new aberrant transcripts due to the use of AONs can make it more difficult
to discern whether it is a real event or an event that is induced or enhanced by the in vitro
delivery of AONs. Moreover, a shorter PE was also detected in the case of c.67-2023T>G
and a larger one in the case of c.4634+741A>G, but both were completely corrected. Overall,
these results indicate how important the position of enhancer motifs within the PE is in
order to achieve high splicing correction. Nevertheless, these side mis-splicing effects could
eventually be corrected by a novel AON design covering that region.
Notably, the ability of AON4 to effectively rescue mis-splicing caused by
c.4539+2001G>A and c.4539+2028C>T in previous studies was translated to c.4539+2064C>T
and c.4539+2065C>G variants as well [30,32]. This AON targets a common SC35 motif
within the PE region associated with the four different variants, and because of their close
proximity in the intron, these variants could be targeted with one single AON. Neverthe-
less, our experiments and earlier research differ in the chemistry of the oligo and the cell
model. In the first case, 2′-OMe-PS chemistry was initially used for AON testing in patient-
derived photoreceptor progenitor cells (PPCs) containing either the c.4539+2001G>A or
the c.4539+2028C>T variant. The 345-nt PE inclusion was not observed in midigene-
transfected HEK293T, and consequently, these variants were analyzed in patient-derived
retina-like cells with endogenous ABCA4 expression. In our case, c.4539+2064C>T and
c.4539+2065C>G variants gave strong PE inclusion in HEK293T which was considered
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sufficient to be targeted with these AONs. However, it might also be interesting to confirm
these observations by investigating these variants in a more retina-like model such as PPCs.
In addition to that, AON17 shows a mismatch with both c.4539+2064C>T and
c.4539+2065C>G, whereas there are no mismatches when targeting the previously re-
ported c.4539+2001G>A and c.4539+2028C>T variants (Supplementary Figure S5). The
selection of AON17 was based on the described high efficiency in PPCs [32] and the posi-
tion within both 345-nt and 170-nt PEs. The other potential candidates with no mismatches
were discarded as they could only target the 345-nt PE introduced by c.4539+2064C>T,
but not the 170-nt PE caused by c.4539+2065C>G. In contrast, AON4 was targeting a
common region in both PEs. While AON4 fully corrected the splicing defect, AON17
only did it partially. When comparing the efficacy of these AONs based on the chemical
modifications, we could indeed see that the 2′-O-MOE-PS AONs were more potent than the
2′-OMe-PS AONs (Supplementary Figure S5). This is in line with previous reports showing
that the 2′-O-MOE-PS AONs have increased potency [39,51]. Previously, we reported
that for this PE insertion, one mismatch was enough to abolish the splicing-switching
capacity of the AON [32]. Nevertheless, this is not the case in this system. In the previous
work, PPCs expressing ABCA4 endogenously were used, while here we used an artificial
overexpression system. Furthermore, AON17 fully binds to the PE carrying the mutation
c.4539+2064C>T (Supplementary Figure S5). This could explain why AON17 performs bet-
ter for this mutation, despite the mismatch. Taken all together, these two AON molecules
are very promising to correct the splicing defects caused by several intronic variants.
Similar results have been obtained when testing AON1 and AON2 for overlapping
PEs caused by c.859-546G>A and c.859-640A>G variants. This represents another clear
example of a mutation-independent concept when designing AONs that can rescue the
same splicing defect, caused by different mutations. Still, this strictly depends on the
position of the PE and how many variants (if any) are detected in a certain intronic region.
In conclusion, it is worth highlighting that the above-mentioned results were obtained with
the midigene system and the efficiency of the AONs may be different from the efficiency
in a retinal environment. Considering the simplified pre-mRNA folding in the midigene
system, it is recommended to translate these assays to retina-like cellular models.
The implications of this study in the current IRD treatment field are mainly related to
the translational properties of AONs and their broad use in the clinical setting. Importantly,
the allelic heterogeneity observed in STGD1 and the variant-dependent disease progression
engages current research with world-wide ABCA4 pathogenic variants identification and,
in parallel, the development of therapies to halt or slow down vision loss. The clinical
presentation of STGD1 is driven by a combination of variants, which can be grouped based
on the proposed severity from deleterious to mild, many of them affecting splicing [13,32].
As a consequence, the combination of variants dictates the onset and progression of the
disease [7].
Ongoing clinical trials are mainly focused on cell replacement therapy, compound
administration and gene augmentation therapy [52–57]. Currently, AON-based therapies
are extensively studied for ABCA4-associated retinopathies due to the high proportion
of splice-affecting variants, yet none have entered clinical trials [18,30–32]. One of the
most advanced clinical trials is the AON-based therapy targeting a recurrent deep-intronic
mutation in CEP290 [21–24,26], which showed improvement in vision during phase 1/2
and allowed the study to proceed to a phase 2/3 pivotal trial [58]. Hence, the increasing
implementation of AONs in the clinical setting contributes to the development of new
strategies for initial in vitro testing of the oligos, including more reliable cell models
and simultaneously expanding the assessment of AON therapeutic efficacy beyond the
RNA level.
As a result of the continuous discovery of pathogenic and rare intronic ABCA4 vari-
ants, AON-based therapy can become part of the rising field of personalized medicine
for IRD patients. Thus, this raises the opportunity to accelerate the treatment of rare
diseases by normalizing N-of-1 clinical trials as previously carried out [59]. In conclusion,
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our results reinforce the use of splicing modulation approaches to effectively rescue the
STGD1 phenotype in the future, making a significant contribution to the development of
personalized medicine.
4. Materials and Methods
4.1. AON Design
For each ABCA4 intronic variant causing PE inclusion, two AONs were designed ac-
cording to previous guidelines described elsewhere. Two particular variants, c.859-640A>G
and c.859-546G>A, led to overlapping PEs and therefore three AONs were designed for
this region of interest. For the exon elongation-causing variants, one or two AONs were
designed aiming to block the new splice site [36,41]. For two variants, c.4539+2064C>T and
c.4539+2065C>G, previously described AONs targeting the same region were used [30,32].
All sequences and properties of the different AONs are described in Table 1. The length,
GC content and Tm of each AON were calculated using online software Oligo Calc:
oligonucleotide properties calculator [60]. The oligonucleotides were purchased from
Eurogentec (Liege, Belgium) and all of them had phosphorothioate (PS) backbone and 2’-O-
methoxyethyl (2′-O-MOE) sugar modification. The PS modifications were not controlled for
stereochemistry. The oligonucleotides were purified using reverse phase high-performance
liquid chromatography to achieve purity of ≥85% according to the manufacturer.
4.2. Generation of ABCA4 Mutant Midigenes
A new mutant construct was obtained for pathogenic variant c.3191-11T>A. To achieve
that, site-directed mutagenesis was performed on wild-type BA16 [16]. Mutagenesis
primers are listed in Supplementary Table S2. The mutagenesis PCR reaction mixture
(50 µL) contained 0.5 µM of each primer, 0.2 mM dNTPs, 1 U Phusion High-Fidelity
DNA Polymerase (New England Biolabs, Ipswich, MA, USA), 1× Phusion HF Buffer, 0.5x
Q-solution (Qiagen, Venlo, The Netherlands), and 40 ng wild-type plasmid as template.
Reaction conditions were set as follows: initial denaturation at 94 ◦C for 5 min; 15 cycles at
94 ◦C for 30 s each, annealing between 55 ◦C and 75 ◦C, and extension at 72 ◦C (1 min/kb),
with a final extension at 72 ◦C for 20 min. PCR products were incubated with DpnI (New
England Biolabs) for 4.5 h at 37 ◦C, followed by heat inactivation at 65 ◦C for 20 min to
digest the wild-type DNA. Subsequently, 5 µL of the digestion were transformed in DH5α.
Upon picking colonies and plasmid isolation, the presence of the mutation was validated
by Sanger sequencing (Supplementary Table S3). Lastly, the validated mutant constructs
were cloned into the Gateway pCI-NEO-RHO destination vector as described in previous
studies [16].
4.3. In Vitro Splice Assay in HEK293T Cells
Human Embryonic Kidney (HEK293T, ATCC# CRL-3216™) cells were cultured in
DMEM supplemented with 10% FBS, 1% penicillin–streptomycin and 1% sodium pyruvate
at 37 ◦C and 5% CO2. To check the effect on splicing of variant c.3191-11T>A in the
newly generated mutant ABCA4 midigenes, HEK293T were seeded in a 12-well plate and
subsequently transfected with 600 ng of either the wild-type or mutant constructs when
70% confluent. Transfections were performed by using FuGENE HD reagent (Promega,
Madison, WI, USA) following manufacturer’s protocol for the ratio 1:3 transfection. Forty-
eight hours post-transfection, cells were harvested for transcriptional analysis by RT-PCR.
4.4. In Vitro AON Rescue Studies Using HEK293T Cells
To assess the efficacy of the AONs, HEK293T cells were seeded in 6-well plates at a
confluence of 70%. After 4 h, when cells were attached, cells were transfected with 1 µg of
the corresponding wild-type or mutant midigene, as well as a non-transfected well which
acted as endogenous control. Midigene constructs and variant-harboring ABCA4 regions
are provided in Figures 2–4. After overnight incubation, cells were trypsinized and divided
into 5 wells of a 24-well plate. Oligonucleotides were resuspended at 100 µM in PBS. When
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completely attached (after 4 h), cells were transfected with 0.5 µM of the corresponding
AONs, or the scramble-oligonucleotide (SON) as negative control. Another well was
left non-treated (NT). Midigene transfections were performed as previously indicated.
Delivery of the AONs was conducted by using 1 µL of FuGENE HD reagent and 0.5 µM
of AON/SON in 50 µL of OptiMEM as previously described elsewhere [36]. Forty-eight
hours post-AON delivery, cells were harvested for transcriptional analysis by RT-PCR. All
experiments were performed in two independent replicates.
4.5. RNA Isolation and RT-PCR Analysis
RNA was isolated from HEK293T cells using the Nucleospin RNA kit (Machery-Nagel,
Düren, Germany) following the manufacturer’s instructions. One microgram of total RNA
was used for cDNA synthesis using iScript cDNA Synthesis kit (Bio-Rad, Hercules, CA,
USA) according to the provider’s protocol. All reverse transcription-PCR (RT-PCR) reaction
mixtures (25 µL) contained 10 µM of each primer pair, 2 mM of dNTPs, 1.5 mM MgCl2,
0.5x Q-solution, 1 U of Taq polymerase and 60 ng of cDNA. PCR conditions were 94 ◦C
for 30 s, followed by 35 cycles of 30 s at 94 ◦C, 30 s at 58 ◦C and 1 min at 72 ◦C, with a
final extension step of 10 min at 72 ◦C. Exon 5 of RHO was used to assess the transfection
efficiency of the midigene constructs. Primer sequences are listed in the Supplementary
Table S4. PCR products were resolved on 2% agarose gels and products were validated
by Sanger sequencing. Semi-quantitative analysis of the bands was performed by using
Fiji software [61] (Supplementary Table S5). Percentage (%) of splicing correction was
calculated from the decrease of aberrant transcript by the AON treatment relative to the
corresponding non-treated mutant condition (Table 1).
4.6. Statistical Analysis
Data were represented as means ± SD and analyzed with GraphPad Prism 9 software
(GraphPad, San Diego, CA, USA). To study the differences between treated and untreated
conditions we implemented the one-way ANOVA test with subsequent Bonferroni cor-
rection. p-values smaller than 0.05 were considered statistically significant as indicated in
the figures.
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Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
.3390/ijms22094621/s1, Figure S1: Genomic regions of interest used for antisense oligonucleotide
(AON) design, Figure S2: Sequence analysis of the resulting RT-PCR products from rescue experi-
ments of near-exon variants causing exon elongation, Figure S3: Sequence analysis of the resulting
RT-PCR products from rescue experiments in deep-intronic variants causing not overlapping pseu-
doexon (PE) inclusion, Figure S4: Sequence analysis of the resulting RT-PCR products from rescue
experiments in deep-intronic variants causing similar pseudoexon (PE) inclusion in the same re-
gion, Figure S5: Aberrant splicing rescue for c.4539+2064C>T and c.4539+2065C>G deep-intronic
variants by 2’-OMe-PS AON4 and AON17. (A) Analysis of splicing correction by reverse transcrip-
tion polymerase chain reaction (RT-PCR) upon AON delivery. Wild-type (WT) midigenes and the
corresponding mutant midigenes containing variants c.4539+2064C>T and c.4539+2065C>G were
transfected in HEK293T, leaving one empty as endogenous HEK293T expression control (END).
The different AONs and a SON (2’-OMe-PS) were then delivered, except for the non-treated lanes
(NT). Genomic region of the different midigenes is depicted on top of each representative RT-PCR
image, whereas the graphs next to each panel represent the semi-quantification of the resulting
RT-PCR products, showing the % of correct and pseudoexon (PE) inclusion transcripts. MQ shows
the negative control of the PCR reaction and amplification of exon 5 of Rhodopsin (RHO) gene was
used as a transfection control. Data (n = 2) are presented as mean ± SD (* p < 0.05, ** p < 0.01,
*** p < 0.001, **** p < 0.0001). (B) Predicted binding of AON17 on target pre-mRNA presenting
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from RT-PCR products. Table S5: Semi-quantification analysis of the RT-PCR products from non-
treated (NT) or AON/SON-treated samples. The amount of the different transcripts is represented
as a percent (%) of the total transcript for each condition or lane. The average of two independent
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standard deviation.
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